Boston Scientific Corporation Q3 2026 Earnings Recap

Boston Scientific fell 5.8% after a sharp Q3 miss and a weaker outlook: organic sales grew 1.5%, below the company’s 3%–5% guide, and Q4 guidance calls for an organic revenue decline of 1%–3%. Beyond the cyber incident’s near-term impact, investors face intensifying EP competition, pressure on WATCHMAN, and management’s warning that 2027 sales and adjusted EPS could be difficult to grow.

Key Takeaways

• Q3 adjusted EPS was $0.73, versus company guidance of $0.80–$0.82; management estimated the cyber incident reduced sales growth by about 300 basis points and adjusted EPS by $0.07.
• For Q4, the company expects organic revenue to decline 1%–3% and adjusted EPS of $0.77–$0.79, citing cyber-related effects, inventory replenishment after elevated customer orders, EP share pressure, and tougher China pricing.
• Full-year 2026 guidance is 4% organic revenue growth and adjusted EPS of $3.16–$3.18. Management expects 2027 to be a trough year and says sales and adjusted EPS may be challenging to grow, excluding Penumbra.
• Performance was uneven: neuromodulation sales grew 13%, while urology declined 3%; U.S. operational sales were flat and Asia Pacific declined 1%.
• Management expects new launches and restructuring actions to support stabilization and a return to growth in 2028, but that recovery is prospective rather than a near-term offset to the outlook.